Miller Anestesia

959 / 2894

133. Baraka A: Onset of neuromuscular block in myas-
thenic patients. Br J Anaesth 69:227-228, 1992.
134. Abel M, Eisenkraft JB: Anesthetic implications of
myasthenia gravis. Mt Sinai J Med 69:31-37, 2002.
135. Takamori M, Maruta T, Komai K: Lambert-Eaton
myasthenic syndrome as an autoimmune calcium-
channelopathy. Neurosci Res 36:183-191, 2000.
136. Hewett SJ, Atchison WD: Serum and plasma from
patients with Lambert-Eaton myasthenic syndrome
reduce depolarization-dependent uptake of 45Ca2 +
into rat cortical synaptosomes. Brain Res 566:320-
324, 1991.
137. Jurkat-Rott K, Lehmann-Horn F: Paroxysmal
muscle weakness: The familial periodic paralyses. J
Neurol 253:1391-1398, 2006.
138. Viscomi CM, Ptacek LJ, Dudley D: Anesthetic
management of familial hypokalemic periodic
paralysis during parturition.Anesth Analg 88:1081-
1082, 1999.
139. Robinson JE, Morin VI, Douglas MJ, Wilson RD:
Familial hypokalemic periodic paralysis and Wolff-
Parkinson-White syndrome in pregnancy. Can J
Anaesth 47:160-164, 2000.
140. Periodic Paralyses. 2007. Available from
Accessed Dec-
ember 2007.
141. Depoix JP, Julliard JM, Aubry P: Propofol-remifen-
tanil target-controlled anesthesia in a patient with
hyperkalemic familial periodic paralysis. Anesth
Analg 99:302, 2004.
142. Aouad R, Atanassoff PG: Epidural anesthesia in a
patient with hyperkalemic periodic paralysis under-
going orthopedic surgery. Can J Anaesth 51:92,
2004.
143. Aarons JJ, Moon RE, Camporesi EM: General anes-
thesia and hyperkalemic periodic paralysis. Anes-
thesiology 71:303-304, 1989.
144. Ashwood EM, Russell WJ, Burrow DD: Hyperkalae-
mic periodic paralysis and anaesthesia. Anaesthesia
47:579-584, 1992.
145. Lehmann-Horn F, Iaizzo PA: Are myotonias and
periodic paralyses associated with susceptibility to
malignant hyperthermia? Br J Anaesth 65:692-697,
1990.
146. Weller JF, Elliott RA, Pronovost PJ: Spinal anesthe-
sia for a patient with familial hyperkalemic periodic
paralysis. Anesthesiology 97:259-260, 2002.
147. Wilson RD, Nichols RJ, Dent TE: Disturbances of
the oxidative-phosphorylation mechanism as a pos-
sible etiological factor in sudden unexplained
hyperthermia occurring during anesthesia. Anes-
thesiology 27:231, 1996.
148. Ording H: Investigation of malignant hyperthermia
susceptibility in Denmark. Dan Med Bull 43:111-
125, 1996.
149. Robinson R, Carpenter D, Shaw MA, et al: Muta-
tions in RYR1 in malignant hyperthermia and
central core disease. Hum Mutat 27:977-989, 2006.
150. Harrison GG, Isaacs H: Malignant hyperthermia.
An historical vignette. Anaesthesia 47:54-56, 1992.
151. Ombrédanne L: De l’influence de l’anesthésique
employé dans la ganèse des accidents post-opéra-
toires de pâleurhyperthermie observés chez les
nourrissons. Rev Med Française 10:617, 1929.
152. Denborough MA, Lovell R: Anaesthetic deaths in a
family. Lancet 2:45, 1960.
153. Kalow W, Britt BA, Terreau ME, Haist C: Metabolic
error of muscle metabolism after recovery from
malignant hyperthermia. Lancet 296:895-898,
1970.
154. Britt BA, Locher WG, Kalow W: Hereditary aspects
of malignant hyperthermia. Can Anaesth Soc J
16:89-98, 1969.
155. Ball RA,Annis CL, Topel DG, Christian LL: Clinical
and laboratory diagnosis of porcine stress syn-
drome. Vet Med Small Anim Clin 68:1156-1159,
1973.
156. Briskey EJ: Etiological status and associated studies
of pale, soft, exudative porcine musculature. Adv
Food Res 13:89-178, 1964.
157. Hall LW, Woolf N, Bradley JW, Jolly DW: Unusual
reaction to suxamethonium chloride. BMJ 2:1305,
1966.
158. Fujii J, Otsu K, Zorzoto F, et al: Identification of a
mutation in porcine ryanodine receptor associated
with malignant hyperthermia. Science 253:448-451,
1991.
159. Harrison GG: Control of the malignant hyper-
pyrexic syndrome in MHS swine by dantrolene
sodium. Br J Anaesth 47:62-65, 1975.
160. Kolb ME, Horne ML, Martz R: Dantrolene in
human malignant hyperthermia. Anesthesiology
56:254-262, 1982.
161. López JR, Alamo LA, Jones D, et al: [Determination
of intracellular free calcium concentration, in vivo,
in swine susceptible to malignant hyperthermia
syndrome.] Acta Cient Venez 36:102-104, 1985.
162. López JR, Alamo LA, Jones D, et al: [Ca2 +]i in
muscles of malignant hyperthermia susceptible pigs
determined in vivo with Ca2+ selective microelec-
trodes. Muscle Nerve 9:85-86, 1986.
163. López JR, Allen PD, Alamo LA, et al: Myoplasmic
free [Ca2+] during a malignant hyperthermia
episode in swine. Muscle Nerve 11:82-88, 1988.
164. López JR, Gerardi A, López MJ,Allen PD: Effects of
dantrolene on myoplasmic free [Ca2 +] measured in
vivo in patients susceptible to malignant hyperther-
mia. Anesthesiology 76:711-719, 1992.
165. Pessah IN,Waterhouse AL, Casida JE: The calcium-
ryanodine receptor complex of skeletal and cardiac
muscle. Biochem Biophys Res Commune 128:449-
456, 1985.
166. Pessah IN, Anderson KW, Casida JE: Solubilization
and separation of Ca2+-ATPase from the Ca2 +-
ryanodine receptor complex. Biochem Biophys Res
Commune 139:235-243, 1986.
167. Beam KG, Tanabe T, Numa S: Structure, function,
and regulation of the skeletal muscle dihydropyri-
dine receptor. Ann N Y Acad Sci 560:127-137,
1989.
168. Tanabe T, Beam KG,Adams BA, et al: Regions of the
skeletal muscle dihydropyridine receptor critical for
excitation-contraction coupling. Nature 346:567-
569, 1990.
169. Nakai J, Tanabe T, Konno T, et al: Localization in the
II-III loop of the dihydropyridine receptor of a
sequence critical for excitation-contraction
coupling. J Biol Chem 273:24983-24986, 1998.
170. Flucher BE, Franzini-Armstrong C: Formation of
junctions involved in excitation-contraction
coupling in skeletal and cardiac muscle. Proc Natl
Acad Sci USA 93:8101-8106, 1996.
171. Cherednichenko G,Hurme AM,Fessenden JD,et al:
Conformational activation of Ca2+ entry by depo-
larization of skeletal myotubes. Proc Natl Acad Sci
USA 101:15793-15798, 2004.
172. Gaburjakova M, Gaburjakova J, Reiken S, et al:
FKBP12 binding modulates ryanodine receptor
channel gating. J Biol Chem 276:16931-16935,
2001.
173. Meissner G: Regulation of mammalian ryanodine
receptors. Front Biosci 7:d2072-d2080, 2002.
174. Ward CW, FengW, Tu J, et al: Homer protein increa-
ses activation of Ca2+ sparks in permeabilized ske-
letal muscle. J Biol Chem 279:5781-5787, 2004.
175. Cherednichenko G,Ward CW, FengW, et al: Enhan-
ced excitation-coupled calcium entry (ECCE) in
myotubes expressing malignant hyperthermia
mutation R163C is attenuated by dantrolene. Mol
Pharmacol 73:1203-1212, 2008.
176. Yang T, Allen PD, Pessah IN, Lopez JR: Enhanced
excitation-coupled calcium entry in myotubes is
associated with expression of RYR1 malignant
hyperthermia mutations. J Biol Chem 282:37471-
37478, 2007.
177. Yang T, Esteve E, Pessah IN, et al: Elevated resting
[Ca2 +](i) in myotubes expressing malignant hyper-
thermia RyR1 cDNAs is partially restored by modu-
lation of passive calcium leak from the SR. Am J
Physiol Cell Physiol 292:C1591-C1598, 2007.
178. Wappler F, Anetseder M, Baur CP, et al: Multicentre
evaluation of in vitro contracture testing with bolus
administration of 4-chloro-m -cresol for diagnosis
of malignant hyperthermia susceptibility. Eur J
Anaesthesiol 20:528-536, 2003.
179. Yang T, Ta TA, Pessah IN, Allen PD: Functional
defects in six ryanodine receptor isoform-1 (RyR1)
mutations associated with malignant hyperthermia
and their impact on skeletal excitation-contraction
coupling. J Biol Chem 278:25722-25730, 2003.
180. Reuter DA, Anetseder M, Müller R, et al: The rya-
nodine contracture test may help diagnose suscep-
tibility to malignant hyperthermia. Can J Anaesth
50:643-648, 2003.
181. Pessah IN, Stambuk RA, Casida JE: Ca2+-activated
ryanodine binding: Mechanisms of sensitivity and
intensity modulation by Mg2 +,caffeine,and adenine
nucleotides. Mol Pharmacol 31:232-238, 1987.
182. Zimanyi I, Pessah IN: Pharmacological characteri-
zation of the specific binding of [3H]ryanodine to
rat brain microsomal membranes. Brain Res
561:181-191, 1991.
183. Jona I, Szegedi C, Sárközi S, et al: Altered inhibition
of the rat skeletal ryanodine receptor/calcium
release channel by magnesium in the presence of
ATP. Pflugers Arch 441:729-738, 2001.
184. Laver D: The power of single channel recording and
analysis: Its application to ryanodine receptors in
lipid bilayers. Clin Exp Pharmacol Physiol 28:675-
686, 2001.
185. Laver DR, Baynes TM, Dulhunty AF: Magnesium
inhibition of ryanodine-receptor calcium channels:
Evidence for two independent mechanisms. J
Membr Biol 156:213-229, 1997.
186. Voss AA,Allen PD, Pessah IN, Perez CF: Allosterica-
lly coupled calcium and magnesium binding sites are
unmasked by ryanodine receptor chimeras.Biochem
Biophys Res Commun 366:988-993, 2008.
187. Lamb GD: Ca 2+ inactivation, Mg2+ inhibition and
malignant hyperthermia. J Muscle Res Cell Motil
14:554-556, 1993.
188. Laver DR, Owen VJ, Juankar PR, et al: Reduced
inhibitory effect of Mg2 + on ryanodine receptor-
Ca2 + release channels in malignant hyperthermia.
Biophys J 73:1913-1924, 1997.
189. Chelu MG, Goonasekera SA, Durham WJ, et al:
Heat- and anesthesia-induced malignant hyper-
thermia in an RyR1 knock-in mouse. FASEB J
20:329-330, 2006.
190. Yang T, Riehl J, Esteve E, et al: Pharmacologic and
functional characterization of malignant hyper-
thermia in the R163C RyR1 knock-in mouse.Anes-
thesiology 105:1164-1175, 2006.
191. López JR, Linares N, Pessah IN, Allen PD: Enhan-
ced response to caffeine and 4-chloro-m-cresol in
malignant hyperthermia–susceptible muscle is
related in part to chronically elevated resting
[Ca2 +]i. Am J Physiol Cell Physiol 288:C606-C612,
2005.
192. Avila G, Dirksen RT: Functional effects of central
core disease mutations in the cytoplasmic region of
Trastornos neuromusculares e hipertermia maligna 959 27
Sección
III
Control de la anestesia
© ELSEVIER. Fotocopiar sin autorización es un delito